10 Life Science Stories to Watch in 2015

BioFlash published an article that looks at 10 major stories life science investors might want to keep an eye on in 2015. Included among them are the continued rise of antibiotics, new competition for drugs for hepatitis C and the launch of the “biggest drug yet” from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX).

Here’s what the news outlet has to say about Vertex:

The Boston-based drug firm’s gamble on its drugs for cystic fibrosis paid off last year, not long after it said it was winding down the program behind its biggest money-maker to date, a drug for hepatitis C, in light of steep competition. That left Vertex (Nasdaq: VRTX) with Kalydeco, its drug for CF, which has been successful but only works in about 5 percent of people with the disease. In June, its next CF drug, lumacaftor — which targets almost half of all people with the disease — showed effectiveness in a late-stage trial; approval this year is expected. No doubt, there will be rejoicing among patients as well as concern over the drug’s cost.

Click here to read the full BioFlash article.